Geng J, Zhao J, Fan R, et al. Global, regional, and national burden and quality of care of multiple myeloma, 1990-2019. J Glob Health. 2024;14:04033. https://doi.org/10.7189/jogh.14.04033.

Article  PubMed  PubMed Central  Google Scholar 

Malard F, Neri P, Bahlis NJ, et al. Multiple myeloma. Nat Rev Dis Primers. 2024;10(1):45. https://doi.org/10.1038/s41572-024-00529-7.

Article  PubMed  Google Scholar 

Dou X, Duan G, Zhong Y, et al. The burden of multiple myeloma in China: trends from 1990 to 2021 and forecasts for 2050. Cancer Lett. 2025;611:217440. https://doi.org/10.1016/j.canlet.2025.217440.

Article  CAS  PubMed  Google Scholar 

Blatter S, Rottenberg S. Minimal residual disease in cancer therapy – small things make all the difference. Drug Resist Updat. 2015;21–22:1–10. https://doi.org/10.1016/j.drup.2015.08.003.

Article  PubMed  Google Scholar 

Rasche L, Schinke C, Maura F, et al. The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states. Nat Commun. 2022;13(1):4517. https://doi.org/10.1038/s41467-022-32145-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Munshi NC, Avet-Loiseau H, Anderson KC, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4(23):5988–99. https://doi.org/10.1182/bloodadvances.2020002827.

Article  PubMed  PubMed Central  Google Scholar 

Perrot A, Lauwers-Cances V, Corre J, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018;132(23):2456–64. https://doi.org/10.1182/blood-2018-06-858613.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cavo M, San-Miguel J, Usmani SZ, et al. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. Blood. 2022;139(6):835–44. https://doi.org/10.1182/blood.2021011101.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oliva S, Bruinink DHO, Rihova L, et al. Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial. Blood Cancer J. 2021;11(6):106. https://doi.org/10.1038/s41408-021-00498-0.

Article  PubMed  PubMed Central  Google Scholar 

Landgren O, Prior TJ, Masterson T, et al. EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma. Blood. 2024;144(4):359–67. https://doi.org/10.1182/blood.2024024371.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shi Q, Paiva B, Pederson LD, et al. Minimal residual disease-based end point for accelerated assessment of clinical trials in multiple myeloma: a pooled analysis of individual patient data from multiple randomized trials. J Clin Oncol. 2025;43(11):1289–301. https://doi.org/10.1200/jco-24-02020.

Article  CAS  PubMed  Google Scholar 

Paiva B, Shi Q, Puig N, et al. Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma. Nat Rev Clin Oncol. 2025;22(6):424–38. https://doi.org/10.1038/s41571-025-01017-x.

Article  PubMed  Google Scholar 

FDA Oncologic Drugs Advisory Committee. i2TEAMM presentation to support MRD as accelerated approval endpoint. 2024. https://www.fda.gov/media/177738/download. Accessed 28 July 2025.

Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–46. https://doi.org/10.1016/S1470-2045(16)30206-6.

Article  PubMed  Google Scholar 

Szalat R, Anderson K, Munshi N. Role of minimal residual disease assessment in multiple myeloma. Haematologica. 2024;109(7):2049–59. https://doi.org/10.3324/haematol.2023.284662.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martinez-Lopez J, Lopez-Muñoz N, Chari A, et al. Measurable residual disease (MRD) dynamics in multiple myeloma and the influence of clonal diversity analyzed by artificial intelligence. Blood Cancer J. 2024;14(1):131. https://doi.org/10.1038/s41408-024-01102-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schmitz A, Brøndum RF, Johnsen HE, et al. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission—results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial. BMC Cancer. 2022;22(1):147. https://doi.org/10.1186/s12885-022-09184-1.

Article  PubMed  PubMed Central  Google Scholar 

Martinez-Lopez J, Wong SW, Shah N, et al. Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma. Blood Adv. 2020;4(14):3295–301. https://doi.org/10.1182/bloodadvances.2020002037.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Paiva B, Manrique I, Dimopoulos MA, et al. MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials. Blood. 2023;141(6):579–91. https://doi.org/10.1182/blood.2022016782.

Article  CAS  PubMed  PubMed Central  Google Scholar 

San-Miguel J, Avet-Loiseau H, Paiva B, et al. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood. 2022;139(4):492–501. https://doi.org/10.1182/blood.2020010439.

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Tute RM, Pawlyn C, Cairns DA, et al. Minimal residual disease after autologous stem-cell transplant for patients with myeloma: prognostic significance and the impact of lenalidomide maintenance and molecular risk. J Clin Oncol. 2022;40(25):2889–900. https://doi.org/10.1200/jco.21.02228.

Article  PubMed  Google Scholar 

Avet-Loiseau H, San-Miguel J, Casneuf T, et al. Evaluation of sustained minimal residual disease negativity with daratumumab-combination regimens in relapsed and/or refractory multiple myeloma: analysis of POLLUX and CASTOR. J Clin Oncol. 2021;39(10):1139–49. https://doi.org/10.1200/jco.20.01814.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Diamond B, Korde N, Lesokhin AM, et al. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2021;8(6):e422–32. https://doi.org/10.1016/s2352-3026(21)00130-7.

Article  CAS  PubMed  Google Scholar 

Alonso R, Cedena MT, Wong S, et al. Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma. Blood Adv. 2020;4(10):2163–71. https://doi.org/10.1182/bloodadvances.2020001508.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cui QQ, Li ZH, Ma YP. MRD dynamics during maintenance therapy in 259 patients with nontransplant eligible multiple myeloma. Leuk Lymphoma. 2024;65(10):1430–7. https://doi.org/10.1080/10428194.2024.2358857.

Article  CAS  PubMed  Google Scholar 

Fan H, Wang W, Zhang Y, et al. Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study. Cancer Biol Med. 2023;20(1):77–87. https://doi.org/10.20892/j.issn.2095-3941.2022.0612.

Article  PubMed  PubMed Central  Google Scholar 

Fonseca R, Arribas M, Wiedmeier-Nutor JE, et al. Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients. Blood Cancer J. 2023;13(1):32. https://doi.org/10.1038/s41408-023-00794-x.

Article  PubMed  PubMed Central